Drugs / Insulin Lispro Mix50
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01773473 | Jan 2013 → Aug 2014 | type 2 diabetes mellitus | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2011-06-24 | Eli Lilly and Company | Results Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S. lilly.com ↗
The analysis indicated that for patients with type 2 diabetes who do not experience frequent hypoglycemia, insulin lispro premixed insulin analogs are likely to be cost-effective when compared to LAIA in the long-term treatment of type 2 diabetes. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2011-06-24 | Eli Lilly and Company | Analysis Compares Cost-Effectiveness of Premixed Insulin Analogs to Long-Acting Insulin Analogs in the Long-Term Treatment of Type 2 Diabetes in the U.S. lilly.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin Lispro Mix50 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01773473 ↗ |
| Known as | LM50 | “compare the efficacy and safety of insulin lispro mix 25 (LM25) and insulin lispro mix 50 (LM50) as starter insulins.” PMID 29574635 ↗ Mar 2018 |
| Route | Subcutaneous | “Administered SC” NCT01773473 ↗ |